Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan

Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan

Bibliographic Details
Main Authors:	Naomi Matsumoto, Junya Shimizu, Yuji Yokoyama, Hirokazu Tsukahara, Takashi Yorifuji
Format:	Article
Language:	English
Published:	Japan Epidemiological Association 2023-02-01
Series:	Journal of Epidemiology
Online Access:	https://www.jstage.jst.go.jp/article/jea/33/2/33_JE20220265/_pdf

Similar Items

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
by: Jolanta Kiewisz, et al.
Published: (2022-04-01)

Association between Dental Caries and Influenza Infection in Children: A Japanese Nationwide Population-Based Study
by: Naomi Matsumoto, et al.
Published: (2021-09-01)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

Current Insights into Atopic March
by: Mitsuru Tsuge, et al.
Published: (2021-11-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01)

Factors Associated with Adverse Reactions to BNT162b2 COVID-19 Vaccine in a Cohort of 3969 Hospital Workers
by: Mario Rivera-Izquierdo, et al.
Published: (2021-12-01)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024-12-01)

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination
by: A-Sol Kim, et al.
Published: (2023-02-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
by: Yoav Rechavi, et al.
Published: (2021-09-01)

Roles of Oxidative Injury and Nitric Oxide System Derangements in Kawasaki Disease Pathogenesis: A Systematic Review
by: Mitsuru Tsuge, et al.
Published: (2023-10-01)

Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age
by: Tan, Sharon H. X., et al.
Published: (2023)

Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers
by: Filippos Filippatos, et al.
Published: (2021-12-01)

Good Immunogenicity of Delayed Second Dose of BNT162b2 Vaccine in Individuals with Acute Allergic-like Reactions after the First Dose
by: Kazuhiro Araki, et al.
Published: (2022-12-01)

Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine
by: Sung-Hee Lim, et al.
Published: (2021-11-01)

The Limited Effect of a History of COVID-19 on Antibody Titers and Adverse Reactions Following BNT162b2 Vaccination: A Single-Center Prospective Study
by: Hisako Kushima, et al.
Published: (2022-09-01)

The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan
by: Toshiya Mitsunaga, et al.
Published: (2021-10-01)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
by: Geon Young Ko, et al.
Published: (2023-10-01)

Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort
by: Oliver Bürzle, et al.
Published: (2023-04-01)

Young Age, Female Sex, and No Comorbidities Are Risk Factors for Adverse Reactions after the Third Dose of BNT162b2 COVID-19 Vaccine against SARS-CoV-2: A Prospective Cohort Study in Japan
by: Ryuta Urakawa, et al.
Published: (2022-08-01)

Detecting time-evolving phenotypic components of adverse reactions against BNT162b2 SARS-CoV-2 vaccine via non-negative tensor factorization
by: Kei Ikeda, et al.
Published: (2022-10-01)

Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS
by: Ming-Ming Yan, et al.
Published: (2022-11-01)

Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions
by: Xin Rong Lim, et al.
Published: (2023-05-01)

Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience
by: Silvia Bloise, et al.
Published: (2022-07-01)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
by: Rumiko Shimazawa, et al.
Published: (2021-12-01)

Antibody Titers After a Third and Fourth SARS-CoV-2 Vaccine Dose in Bizen City, Japan
by: Tomoka Kadowaki, et al.
Published: (2023-09-01)

Twenty-Month Monitoring of Humoral Immune Response to BNT162b2 Vaccine: Antibody Kinetics, Breakthrough Infections, and Adverse Effects
by: Jaroslaw Walory, et al.
Published: (2023-10-01)

Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers
by: Jun Otani, et al.
Published: (2021-10-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Evaluation of the association of birth order and group childcare attendance with Kawasaki disease using data from a nationwide longitudinal survey
by: Takahiro Namba, et al.
Published: (2023-03-01)

Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster
by: Wagenhäuser, I, et al.
Published: (2023)

The Influence of Time of Day of Vaccination with BNT162b2 on the Adverse Drug Reactions and Efficacy of Humoral Response against SARS-CoV-2 in an Observational Study of Young Adults
by: Paweł Matryba, et al.
Published: (2022-03-01)

Treatment interruption in hypertensive patients during the COVID‐19 pandemic: An interrupted time series analysis using prescription data in Okayama, Japan
by: Naoko Nakamura, et al.
Published: (2024-03-01)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
by: Merav Mofaz, et al.
Published: (2022-07-01)

Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing
by: Hideharu Hagiya, et al.
Published: (2022-11-01)

The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study
by: Daisuke Jubishi, et al.
Published: (2022-11-01)

Effectiveness, Adverse Events, and Immune Response Following Double Vaccination with BNT162b2 in Staff at the National Comprehensive Cancer Center (NCCC)
by: Patrik Palacka, et al.
Published: (2022-04-01)

The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
by: Andrea Picchianti Diamanti, et al.
Published: (2023-02-01)

Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination
by: Ryousuke Koike, et al.
Published: (2022-03-01)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
by: Itzchak Levy, et al.
Published: (2022-07-01)